Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 2
2012 2
2013 2
2014 3
2015 3
2016 4
2017 5
2018 1
2019 5
2021 4
2022 5
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
The pro- and anti-tumor role of ILC2s.
Trabanelli S, Chevalier MF, Derré L, Jandus C. Trabanelli S, et al. Among authors: chevalier mf. Semin Immunol. 2019 Feb;41:101276. doi: 10.1016/j.smim.2019.04.004. Epub 2019 May 23. Semin Immunol. 2019. PMID: 31130471 Review.
The multifaceted immune regulation of bladder cancer.
Schneider AK, Chevalier MF, Derré L. Schneider AK, et al. Among authors: chevalier mf. Nat Rev Urol. 2019 Oct;16(10):613-630. doi: 10.1038/s41585-019-0226-y. Epub 2019 Sep 9. Nat Rev Urol. 2019. PMID: 31501534 Review.
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Derré L, et al. Among authors: chevalier mf. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. J Immunother Cancer. 2023. PMID: 38101861 Free PMC article.
Immunotherapeutic strategies for bladder cancer.
Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L. Chevalier MF, et al. Hum Vaccin Immunother. 2014;10(4):977-81. doi: 10.4161/hv.27621. Epub 2014 Jan 2. Hum Vaccin Immunother. 2014. PMID: 24384699 Free PMC article.
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S, Chevalier MF, Verardo M, Nguyen S, Cesson V, Schneider AK, Dartiguenave F, Rodrigues-Dias SC, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Benmerzoug S, et al. Among authors: chevalier mf. Eur Urol Focus. 2022 May;8(3):748-751. doi: 10.1016/j.euf.2021.06.001. Epub 2021 Jun 17. Eur Urol Focus. 2022. PMID: 34147404 Free article.
Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphoma.
Cuffel A, Allain V, Faivre L, Di Blasi R, Morin F, Vercellino L, Chevalier MF, Desnoyer A, de Jorna R, Madelaine I, Parquet N, Brignier AC, Thieblemont C, Larghero J, Caillat-Zucman S, Mebarki M. Cuffel A, et al. Among authors: chevalier mf. Blood Adv. 2022 Aug 9;6(15):4657-4660. doi: 10.1182/bloodadvances.2022007057. Blood Adv. 2022. PMID: 35728051 Free PMC article. No abstract available.
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, Morita H, Pizzitola I, Grandclément C, Bohner P, Bruni E, Girotra M, Pallavi R, Falvo P, Leibundgut EO, Baerlocher GM, Carlo-Stella C, Taurino D, Santoro A, Spinelli O, Rambaldi A, Giarin E, Basso G, Tresoldi C, Ciceri F, Gfeller D, Akdis CA, Mazzarella L, Minucci S, Pelicci PG, Marcenaro E, McKenzie ANJ, Vanhecke D, Coukos G, Mavilio D, Curti A, Derré L, Jandus C. Trabanelli S, et al. Among authors: chevalier mf. Nat Commun. 2017 Sep 19;8(1):593. doi: 10.1038/s41467-017-00678-2. Nat Commun. 2017. PMID: 28928446 Free PMC article.
33 results